AlzeCure Pharma
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sl… Read more
AlzeCure Pharma (ALZCUR) - Total Assets
Latest total assets as of September 2025: Skr66.59 Million SEK
Based on the latest financial reports, AlzeCure Pharma (ALZCUR) holds total assets worth Skr66.59 Million SEK as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AlzeCure Pharma - Total Assets Trend (2017–2024)
This chart illustrates how AlzeCure Pharma’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AlzeCure Pharma - Asset Composition Analysis
Current Asset Composition (December 2024)
AlzeCure Pharma's total assets of Skr66.59 Million consist of 99.4% current assets and 0.7% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 91.5% |
| Accounts Receivable | Skr2.71 Million | 7.9% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr207.00K | 0.6% |
| Intangible Assets | Skr17.00K | 0.1% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2017–2024)
This chart illustrates how AlzeCure Pharma's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AlzeCure Pharma's current assets represent 99.4% of total assets in 2024, a decrease from 99.5% in 2017.
- Cash Position: Cash and equivalents constituted 91.5% of total assets in 2024, down from 96.4% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
AlzeCure Pharma Competitors by Total Assets
Key competitors of AlzeCure Pharma based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
AlzeCure Pharma - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AlzeCure Pharma generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AlzeCure Pharma is currently not profitable relative to its asset base.
AlzeCure Pharma - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.75 | 6.02 | 16.38 |
| Quick Ratio | 4.75 | 6.02 | 16.38 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr49.12 Million | Skr 35.36 Million | Skr 108.79 Million |
AlzeCure Pharma - Advanced Valuation Insights
This section examines the relationship between AlzeCure Pharma's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.30 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | Skr34.44 Million |
| Market Capitalization | $12.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values AlzeCure Pharma's assets below their book value (0.36 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: AlzeCure Pharma's assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AlzeCure Pharma (2017–2024)
The table below shows the annual total assets of AlzeCure Pharma from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Skr34.44 Million | +7.61% |
| 2023-12-31 | Skr32.00 Million | -54.82% |
| 2022-12-31 | Skr70.84 Million | +55.18% |
| 2021-12-31 | Skr45.65 Million | -61.26% |
| 2020-12-31 | Skr117.83 Million | -36.91% |
| 2019-12-31 | Skr186.75 Million | -21.46% |
| 2018-12-31 | Skr237.78 Million | +324.83% |
| 2017-12-31 | Skr55.97 Million | -- |